Arthur A. Levin

11.1k citations

114 papers · 8.2k indexed · 3 hit papers · h-index 44

Impact in

Cancer Research top 0.5%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
Molecular Biology top 0.5%
- RNA Interference and Gene Delivery
- Retinoids in leukemia and cellular processes
- Advanced biosensing and bioanalysis techniques
- DNA and Nucleic Acid Chemistry
- Circular RNAs in diseases

Papers in

Biochemistry 8
- Antioxidant Activity and Oxidative Stress 8
Molecular Biology 73
- DNA and Nucleic Acid Chemistry 25
- Retinoids in leukemia and cellular processes 23
- Advanced biosensing and bioanalysis techniques 21
- RNA Interference and Gene Delivery 20
- RNA and protein synthesis mechanisms 6

Co-authors: Richard S. Geary Joseph F. Grippo Scott P. Henry Gary Allenby Angela L. Purcell Eva van Rooij J Speck Michael R. Hodges
Journals: Toxicology and Applied Pharmacology (7 papers)Journal of Pharmacology and Experimental Therapeutics (5 papers)Nucleic Acid Therapeutics (4 papers)New England Journal of Medicine (4 papers)Journal of Pharmaceutical Sciences (3 papers)
Partner nations: United States Switzerland Canada

In The Last Decade

Arthur A. Levin

109 papers receiving 7.9k citations

Hit Papers

align trajectories log scale

Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study 2020 · 266 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 European Heart Journal
2013 New England Journal of Medicine
1992 Nature

Peers

Countries citing papers authored by Arthur A. Levin

Since Specialization

Citations

This map shows the geographic impact of Arthur A. Levin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arthur A. Levin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arthur A. Levin more than expected).

Fields of papers citing papers by Arthur A. Levin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arthur A. Levin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arthur A. Levin. The network helps show where Arthur A. Levin may publish in the future.

Co-authors

The 25 scholars most cited alongside Arthur A. Levin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Arthur A. Levin Line = papers co-authored together Arthur A. Levin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Assessing Hybridization-Dependent Off-Target Risk for Therapeutic Oligonucleotides: Updated Industry Recommendations Nucleic Acid Therapeutics ·Patrik Andersson, Sebastien A. Burel, Heather Estrella, Jeffrey W.-D. Foy, Peter Hagedorn, Євген Лісов, Scott P. Henry, Jean-Christophe Hoflack, Erle M. Holgersen, Arthur A. Levin, Perlyne Kugler, Adam Pavlı́c̀ek, Cris G. Ebby, Utsav Saxena	2025	3
2	Structure–Activity Relationship of Antibody–Oligonucleotide Conjugates: Evaluating Bioconjugation Strategies for Antibody–siRNA Conjugates for Drug Development Journal of Medicinal Chemistry ·Michael A. Cochran, 石崎正和, Rob S. Burke, David I. Chu, 浩司今泉, Michael Hood, 剛士平本, Floresmilda Cruz Chinguel, Yanling Chen, Michael Moon, Christopher D. Miller, Hanhua Huang, Arthur A. Levin, Venkata Ramana Doppalapudi	2024	13
3	Targeted tissue delivery of RNA therapeutics using antibody–oligonucleotide conjugates (AOCs) Nucleic Acids Research ·Barbora Malecová, Rob S. Burke, Michael A. Cochran, 侯金香, Rachel Johns, 剛士平本, Venkata Ramana Doppalapudi, 浩司今泉, 太郎綿末, Beatrice Darimont, Christopher Miller, Hanhua Huang, Andrew J. Geall, Husam S. Younis, Arthur A. Levin	2023	75
4	DUX4 siRNA Optimization for the Development of an Antibody-Oligonucleotide Conjugate (AOC) for the Treatment of FSHD (P17-13.009) Neurology ·Barbora Malecová, David Sala, zohre saeidi, 浩司今泉, Rachel Johns, Joanne Young, Erwann Ventre, Sole Gatto, Matthew Onorato, Adam Pavlı́c̀ek, Orsolya Király, 博谷口, Arthur A. Levin, Philipp Hadwiger, WG Bertrams, Mark Stahl	2022	2
5	Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study European Heart Journal ·Jörg Täubel, Wilfried Hauke, Steffen Rump, Janika Viereck, Sándor Bátkai, Zahra Yekanipour, 松本学, Henning Weigt, Celina Genschel, Ulrike Lorch, Carmen Theek, Arthur A. Levin, Johann Bauersachs, Scott D. Solomon, Thomas Thum Hit paper breakdown →	2020	266
6	Targeting Therapeutic Oligonucleotides New England Journal of Medicine ·Arthur A. Levin	2017	26
7	Oligo Safety Working Group Exaggerated Pharmacology Subcommittee Consensus Document Nucleic Acid Therapeutics ·Doug Kornbrust, Joy Cavagnaro, Arthur A. Levin, Jeffrey W.-D. Foy, P A Pavco, Christina Gamba‐Vitalo, Alain Guimond	2013	32
8	Acute Kidney Injury During Therapy With an Antisense Oligonucleotide Directed Against PCSK9 American Journal of Kidney Diseases ·Eveline P. van Poelgeest, Y. M. Cho, Michiel G.H. Betjes, Matthijs Moerland, Jan J. Weening, C. Billi, Michael R. Hodges, Arthur A. Levin, Jacobus Burggraaf	2013	73
9	Distribution and Excretion of a Phosphorothioate Oligonucleotide in Rats with Experimentally Induced Renal Injury Oligonucleotides ·David Wolfmeyer, Ann de Peyster, Arthur A. Levin, David Monteith	2004	10
10	Liarozole Markedly Increases all trans-Retinoic Acid Toxicity in Mouse Limb Bud Cell Cultures: A Model to Explain the Potency of the Aromatic Retinoid (E)-4-[2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthylenyl)-1-propenyl] Benzoic Acid Toxicology and Applied Pharmacology ·Natalija Cvjetićanin, Frederick C. Kauffman, Arthur A. Levin	2002	10
11	Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide International Immunopharmacology ·Scott P. Henry, Greg Beattie, Grace Chao Yeh, Gregorius Armando Malvin, Patricia C. Giclas, Angela Mortari, Mark A. Jagels, Douglas J. Kornbrust, Arthur A. Levin	2002	110
12	Pharmacokinetic and Toxicity Profile of a Phosphorothioate Oligonucleotide Following Inhalation Delivery to Lung in Mice Antisense and Nucleic Acid Drug Development ·Michael V. Templin, Arthur A. Levin, Mark J. Graham, Per M. Åberg, Bengt Axelsson, Madeline Butler, Richard S. Geary, C. Frank Bennett	2000	46
13	A Nonradioisotope Biomedical Assay for Intact Oligonucleotide and Its Chain-Shortened Metabolites Used for Determination of Exposure and Elimination Half-Life of Antisense Drugs in Tissue Analytical Biochemistry ·Richard S. Geary, John Matson, Arthur A. Levin	1999	26
14	Receptors as tools for understanding the toxicity of retinoids Toxicology Letters ·Arthur A. Levin	1995	11
15	Conformationally Defined 6-s-trans-Retinoic Acid Analogs. 2. Selective Agonists for Nuclear Receptor Binding and Transcriptional Activity Journal of Medicinal Chemistry ·Donghua Fan, Olivia Romarito Samosir, Brahma P. Sani, Pratap Venepally, Arthur A. Levin, Sonja Kazmer, Ellen Li, Andrew W. Norris, Xiao-kun Zhang	1995	16
16	Distinct Binding Determinants for 9- cis Retinoic Acid Are Located within AF-2 of Retinoic Acid Receptor α Molecular and Cellular Biology ·Bonnie F. Tate, Gary Allenby, Zeinab Salim, Sonja Kazmer, J Speck, Laurie J. Sturzenbecker, P Abarzúa, Arthur A. Levin, Joseph F. Grippo	1994	6
17	The discovery of 9-cis retinoic acid a hormone that binds the retinoid-X receptor Trends in Endocrinology and Metabolism ·Bonnie F. Tate, Arthur A. Levin, Joseph F. Grippo	1994	25
18	Retinoids for the future: Investigational approaches for the identification of new compounds Journal of the American Academy of Dermatology ·R. B. Armstrong, Hee-Joong Kim, Joseph F. Grippo, Arthur A. Levin	1992	16
19	Health services : the local perspective DigitalGeorgetown (Georgetown University Library) ·Arthur A. Levin	1977	7
20	The life and work of Mikhail Osipovich Gershenzon (1869-1925) : a study in the history of the Russian silver age University Microfilms International eBooks ·Arthur A. Levin	1968	3

About Arthur A. Levin

Arthur A. Levin is a scholar working on Biochemistry, Molecular Biology, Genetics, Biochemistry and Hematology, having authored 114 papers that have together received 8.2k indexed citations. Recurring topics across this work include DNA and Nucleic Acid Chemistry (25 papers), Retinoids in leukemia and cellular processes (23 papers), Advanced biosensing and bioanalysis techniques (21 papers), RNA Interference and Gene Delivery (20 papers), Estrogen and related hormone effects (20 papers), Antioxidant Activity and Oxidative Stress (8 papers), RNA and protein synthesis mechanisms (6 papers) and Nuclear Receptors and Signaling (6 papers). The work is most often cited by research in Cancer Research (2.0k citations), Molecular Biology (6.0k citations), Biochemistry (522 citations), Genetics (1.3k citations) and Immunology (904 citations). Arthur A. Levin has collaborated with scholars based in United States, Switzerland and Canada. Frequent co-authors include Richard S. Geary, Joseph F. Grippo, Scott P. Henry, Gary Allenby, Angela L. Purcell, Eva van Rooij, J Speck, Michael R. Hodges, Thomas Bosakowski and Sonja Kazmer. Their work appears in journals such as Toxicology and Applied Pharmacology, Journal of Pharmacology and Experimental Therapeutics, Nucleic Acid Therapeutics, New England Journal of Medicine and Journal of Pharmaceutical Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact